Genetic modulation of adenosine receptor function and adenosine handling in murine hearts: Insights and issues

Journal of Molecular and Cellular Cardiology

Volumn 42, Issue 4, 2007, Pages 693-705

  Ashton, Kevin J ^a   Peart, Jason N ^a   Morrison, R Ray ^b   Matherne, G Paul ^d   Blackburn, Michael R ^c   Headrick, John P ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Adenosine; Adenosine receptor; Cardioprotection; Coronary; Gene knockout; Infarction; Inflammation; Ischemia reperfusion; Myocardial; Preconditioning; Transgenic models

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2 A RECEPTOR; ADENOSINE A2 B RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; UNCLASSIFIED DRUG;

CARDIOVASCULAR SYSTEM; CELL DAMAGE; CELL DEATH; GENE DELETION; GENE OVEREXPRESSION; GENETIC MANIPULATION; HEART; HEART BLOOD VESSEL; HEART PROTECTION; HYPOXIA; INTROSPECTION; ISCHEMIA; NONHUMAN; PHENOTYPE; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ADENOSINE; ANIMALS; CARDIOVASCULAR DISEASES; HEART; MICE; PHENOTYPE; RECEPTORS, PURINERGIC P1;

MURINAE;

EID: 34047092225     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.12.012     Document Type: Review

References (159)

1. Shryock J.C., and Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol. 79 (1997) 2-10
2. Abbracchio M.P., and Burnstock G. Purinergic signalling: pathophysiological roles. Jpn. J. Pharmacol. 78 (1998) 113-145
3. Ralevic V., and Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50 (1998) 413-492
4. Mubagwa K., and Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc. Res. 52 (2001) 25-39
5. Tabrizchi R., and Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol. Ther. 91 (2001) 133-147
6. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 364-373
7. Headrick J.P., Hack B., and Ashton K.J. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am. J. Physiol.: Heart Circ. Physiol. 285 (2003) H1797-H1818
8. Linden J. Adenosine in tissue protection and tissue regeneration. Mol. Pharmacol. 67 (2005) 1385-1387
9. Newby A.C., Worku Y., and Holmquist C.A. Adenosine formation. Evidence for a direct biochemical link with energy metabolism. Adv. Myocardiol. 6 (1985) 273-284
10. Riksen N.P., Rongen G.A., Blom H.J., Boers G.H., and Smits P. Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia. Clin. Chem. Lab. Med. 43 (2005) 1001-1006
11. Willems L., Ashton K.J., and Headrick J.P. Adenosine-mediated cardioprotection in the aging myocardium. Cardiovasc. Res. 66 (2005) 245-255
12. De Tata V., Gini S., Simonetti I., Fierabracci V., Gori Z., Ipata P.L., et al. The regional distribution of adenosine-regulating enzymes in the left and right ventricle walls of control and hypertrophic heart. Basic Res. Cardiol. 84 (1989) 597-605
13. 2-receptor stimulation in the isoproterenol-stimulated ventricular myocytes of spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 31 (1998) 493-498
14. Meyer T.E., Chung E.S., Perlini S., Norton G.R., Woodiwiss A.J., Lorbar M., et al. Antiadrenergic effects of adenosine in pressure overload hypertrophy. Hypertension 37 (2001) 862-868
15. Zhao X.H., Sun X.Y., Erlinge D., Edvinsson L., and Hedner T. Downregulation of adenosine and P2X receptor-mediated cardiovascular responses in heart failure rats. Blood Pressure 9 (2000) 152-161
16. Dubey R., Mi Z., Gillespie D.G., and Jackson E.K. Dysregulation of extracellular adenosine levels by vascular smooth muscle cells from spontaneously hypertensive rats. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 249-254
17. Jacobson K.A., and Gao Z.G. Adenosine receptors as therapeutic targets. Nat. Rev., Drug Discov. 5 (2006) 247-264
18. Fredholm B.B., Jzerman IA.P., Jacobson K.A., Klotz K.N., and Linden J. International Union of Pharmacology: XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53 (2001) 527-552
19. Bolling S.F., Childs K.F., and Ning X.H. Adenosine's effect on myocardial functional recovery: substrate or signal?. J. Surg. Res. 57 (1994) 591-595
20. Peart J., Willems L., and Headrick J.P. Receptor and non-receptor-dependent mechanisms of cardioprotection with adenosine. Am. J. Physiol.: Heart Circ. Physiol. 284 (2003) H519-H527
21. Gelpi R.J., Morales C., Cohen M.V., and Downey J.M. Xanthine oxidase contributes to preconditioning's preservation of left ventricular developed pressure in isolated rat heart: developed pressure may not be an appropriate end-point for studies of preconditioning. Basic Res. Cardiol. 97 (2002) 40-46
22. Becker L.B. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc. Res. 61 (2004) 461-470
23. 2 receptor and an intracellular site. Eur. J. Pharmacol. 96 (1983) 61-69
24. Lewis C.D., Hourani S.M.O., Long C.J., and Collis M.G. Characterisation of adenosine receptors in the rat isolated aorta. Gen. Pharmacol. 25 (1994) 1381-1387
25. 6-cyclopentyladenosine. J. Pharmacol. Exp. Ther. 270 (1994) 893-899
26. Knight G.E., and Burnstock G. The effects of purine compounds on the isolated aorta of the frog Rana temporaria. Br. J. Pharmacol. 117 (1996) 873-878
27. Prentice D.J., Payne S.L., and Hourani S.M.O. Activation of two sites by adenosine receptor agonists to cause relaxation in rat isolated mesenteric artery. Br. J. Pharmacol. 122 (1997) 1509-1515
28. Prentice D.J., and Hourani S.M.O. Characterisation of adenosine receptors mediating relaxation in hamster isolated aorta. Naunyn-Schmiedeberg's Arch. Pharmacol. 362 (2000) 427-434
29. 3 receptors. Eur. J. Pharmacol. 415 (2001) 251-255
30. Lee J.E., Bokoch G., and Liang B.T. A novel cardioprotective role of RhoA: new signaling mechanism for adenosine. FASEB J. 15 (2001) 1886-1894
31. Klinger M., Freissmuth M., and Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell. Signal. 14 (2002) 99-108
32. Schulte G., and Fredholm B.B. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell. Signal. 15 (2003) 813-827
33. Germack R., and Dickenson J.M. Characterization of ERK1/2 signalling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes. Br. J. Pharmacol. 141 (2004) 329-339
34. 2B receptors. Pharmacol. Rev. 49 (1997) 381-402
35. 2b receptor cascade. Cardiovasc. Res. 70 (2006) 308-314
36. Krieg T., Qin Q., McIntosh E.C., Cohen M.V., and Downey J.M. ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases. Am. J. Physiol.: Heart Circ. Physiol. 283 (2002) H2322-H2330
37. 2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway. J. Cardiovasc. Pharmacol. 43 (2004) 416-422
38. 3 receptor-mediated regulation of p38 and extracellular-regulated kinase ERK1/2 via phosphatidylinositol-3′-kinase. Biochem. Pharmacol. 67 (2004) 129-134
39. Yang X.M., Krieg T., Cui L., Downey J.M., and Cohen M.V. NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J. Mol. Cell. Cardiol. 36 (2004) 411-421
40. 1 receptor mediated protection of the globally ischemic isolated rat heart. J. Mol. Cell. Cardiol. 22 (1990) 39-47
41. 1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 6541-6546
42. 2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene. Oncogene 13 (1996) 1471-1482
43. Ledent C., Coppee F., Dumont J.E., Vassart G., and Parmentier M. Transgenic models for proliferative and hyperfunctional thyroid diseases. Exp. Clin. Endocrinol. Diabetes 104 Suppl. 3 (1996) 43-46
44. 1 adenosine receptors. Hypertension 46 (2005) 780-786
45. 1 adenosine receptors in the heart. Drug Dev. Res. 45 (1998) 402-409
46. 1 adenosine receptor. Am. J. Physiol.: Heart Circ. Physiol. 285 (2003) H145-H153
47. 1 receptor system. Cardiovasc. Res. 27 (1993) 28-35
48. 1 adenosine receptors mimics ischemic preconditioning. Am. J. Physiol.: Heart Circ. Physiol. 279 (2000) H1071-H1078
49. 1-adenosine receptor protects intact mice against myocardial infarction. Am. J. Physiol.: Heart Circ. Physiol. 282 (2002) H949-H955
50. 1 adenosine receptor overexpression attenuates ischemia-reperfusion-induced apoptosis and caspase 3 activity. Am. J. Physiol.: Heart Circ. Physiol. 284 (2003) H859-H866
51. 1 adenosine receptor overexpression markedly improves myocardial energy state during ischemia-reperfusion. J. Mol. Cell. Cardiol. 30 (1998) 1059-1064
52. 1 adenosine receptor overexpression on sarcoplasmic reticulum function. Cardiovasc. Res. 53 (2002) 326-333
53. 1 adenosine receptor overexpression. J. Physiol. (Lond.) 549 (2003) 823-833
54. 1-adenosine receptors. Br. J. Pharmacol. 128 (1999) 1623-1629
55. 1-adenosine receptors. Br. J. Pharmacol. 138 (2003) 209-217
56. 1-adenosine receptors. Cardiovasc. Res. 60 (2003) 529-537
57. 1 adenosine receptor limits myocardial ischemic tolerance. Circ. Res. 96 (2005) 363-367
58. 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9407-9412
59. 1 receptors. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9983-9988
60. 1 adenosine receptors in regulation of vascular tone. Am. J. Physiol.: Heart Circ. Physiol. 288 (2005) H1411-H1416
61. 1 adenosine receptor in the regulation of coronary flow. Am. J. Physiol.: Heart Circ. Physiol. 291 (2006) H467-H472
62. 3H]8-cyclopentyl-1,3-dipropylxanthine in coronary smooth muscle. Circ. Res. 77 (1995) 194-198
63. 1 receptors are necessary for protection of the murine heart by remote, delayed adaptation to ischaemia. Acta Physiol. Scand. 182 (2004) 133-143
64. 1 adenosine receptor expression on protection with ischemic preconditioning. Am. J. Physiol.: Heart Circ. Physiol. 290 (2006) H1469-H1473
65. 1 receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischaemia. Cardiovasc. Res. 28 (1994) 270-279
66. 1 receptor stimulation during reperfusion following ischaemia. Br. J. Pharmacol. 118 (1996) 355-363
67. 1 adenosine receptor activation during ischemia or reperfusion improves recovery in mouse hearts. Am. J. Physiol.: Heart Circ. Physiol. 279 (2000) H2166-H2175
68. 1 adenosine receptors on postischemic cardiac function and expression of adenosine receptor subtypes. Am. J. Physiol.: Heart Circ. Physiol. 291 (2006) H1875-H1882
69. Harrison G.J., Willis R.J., and Headrick J.P. Extracellular adenosine levels and cellular energy metabolism in ischemically preconditioned rat heart. Cardiovasc. Res. 40 (1998) 74-87
70. Mortimer S.L., Kodl C.T., Reiling C.R., and Van Wylen D.G.L. Preconditioning-induced attenuation of purine metabolite accumulation during ischemia: memory and multiple cycles. Basic Res. Cardiol. 95 (2000) 119-126
71. Headrick J.P., Peart J., Hack B., Flood A., and Matherne G.P. Functional properties and responses to ischemia reperfusion in Langendorff perfused mouse hearts. Exp. Physiol. 86 (2001) 703-716
72. Li G., Tokuno S., Thaepold P., Vaage J., Lowbeer C., and Valen G. Preconditioning protects the severely atherosclerotic mouse heart. Ann. Thorac. Surg. 71 (2001) 1296-1304
73. Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype?. Trends Neurosci. 19 (1996) 177-181
74. 2A receptor. Nature 388 (1997) 674-678
75. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19 (1999) 9192-9200
76. 2B receptors. Am. J. Physiol.: Heart Circ. Physiol. 282 (2002) H437-H444
77. 2B receptors in mice. J. Cardiovasc. Pharmacol. 41 (2003) 562-570
78. 2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111 (2005) 2190-2197
79. Flood A., and Headrick J.P. Functional characterization of coronary vascular adenosine receptors in the mouse. Br. J. Pharmacol. 133 (2001) 1063-1072
80. 2A adenosine receptor mediates coronary vasodilation. J. Pharmacol. Exp. Ther. 284 (1998) 1066-1073
81. Lew M.J., and Kao S.W. Examination of adenosine receptor-mediated relaxation of the pig coronary artery. Clin. Exp. Pharmacol. Physiol. 26 (1999) 438-443
82. 2B receptors. Br. J. Pharmacol. 126 (1999) 1796-1800
83. Hinschen A.K., Rose'Meyer R.B., and Headrick J.P. Adenosine receptor subtypes mediating coronary vasodilation in rat hearts. J. Cardiovasc. Pharmacol. 41 (2003) 73-80
84. Talukder M.A., Morrison R.R., and Mustafa S.J. Comparison of the vascular effects of adenosine in isolated mouse heart and aorta. Am. J. Physiol.: Heart Circ. Physiol. 282 (2002) H49-H57
85. 2A receptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 366 (2002) 127-133
86. Scislo T.J., and O'Leary D.S. Purinergic mechanisms of the nucleus of the solitary tract and neural cardiovascular control. Neurol. Res. 27 (2005) 182-194
87. 2A-receptor knockout mice, but not in wild-type mice. Neuropsychopharmacology 30 (2005) 1856-1860
88. Cronstein B.N. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 76 (1994) 5-13
89. Vinten-Johansen J., Thourani V.H., Ronson R.S., Jordan J.E., Zhao Z.Q., Nakamura M., et al. Broad-spectrum cardioprotection with adenosine. Ann. Thorac. Surg. 68 (1999) 1942-1948
90. 2A receptors. Annu. Rev. Immunol. 22 (2004) 657-682
91. 2A adenosine receptor-mediated mechanisms of tissue protection. Drug Discov. Today 9 (2004) 403-409
92. 2 receptor function in rat ventricular myocytes. Cardiovasc. Res. 34 (1997) 337-347
93. 2a agonist CGS-21680 in infarcted and stunned porcine myocardium. Am. J. Physiol.: Heart Circ. Physiol. 280 (2001) H1660-H1666
94. 2A receptor agonists. Br. J. Pharmacol. 132 (2001) 1017-1026
95. 2A subtype adenosine receptor in the anti-inflammatory interactions of CGS 21680, cyclopentyladenosine, and IB-MECA with human neutrophils. Biochem. Pharmacol. 60 (2000) 993-999
96. 2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J. Pharmacol. Exp. Ther. 280 (1997) 301-309
97. 2A receptors. J. Auton. Pharm. 21 (2001) 263-271
98. Peart J., Flood A., Linden J., Matherne G.P., and Headrick J.P. Adenosine-mediated cardioprotection in ischemic-reperfused mouse heart. J. Cardiovasc. Pharmacol. 39 (2002) 117-129
99. 2 receptors. J. Cardiovasc. Pharmacol. 38 (2001) 474-481
100. 2A receptor agonists in the isolated rat heart. Pharmacol. Res. 35 (1997) 57-64
101. 2A receptor in the modulation of myocardial reperfusion damage. J. Cardiovasc. Pharmacol. 33 (1999) 883-893
102. Kin H., Zatta A.J., Lofye M.T., Amerson B.S., Halkos M.E., Kerendi F., et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc. Res. 67 (2005) 124-133
103. 2b receptor antagonist ZM241385 blocks the cardioprotective effect of adenosine receptor agonist pretreatment in in vivo rat myocardium. Am. J. Physiol.: Heart Circ. Physiol. (2006) [Epub ahead of print]
104. 2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am. J. Physiol.: Gastrointest. Liver Physiol. 286 (2004) G285-G293
105. 2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat. Med. 10 (2004) 1081-1087
106. 2A adenosine receptor on the profile of chemokines produced by neutrophils. FASEB J. 20 (2006) 187-189
107. 2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111 (2005) 2190-2197
108. + T-lymphocytes. Circulation 114 (2006) 2056-2064
109. 2A receptors. Am. J. Pathol. 160 (2002) 2009-2018
110. 2A receptor agonists and endotoxin. Am. J. Pathol. 160 (2002) 2231-2244
111. 2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. Mol. Pharmacol. 67 (2005) 1406-1413
112. 3 adenosine receptors. Circ. Res. 92 (2003) 485-492
113. 2B receptors in angiogenic factor regulation. Circ. Res. 90 (2002) 531-538
114. 2B adenosine receptors stimulate growth of porcine and rat arterial endothelial cells. Hypertension 39 (2002) 530-535
115. 2B adenosine receptor mRNA. Circ. Res. 93 (2003) 500-506
116. 2b receptor cascade. Cardiovasc. Res. 70 (2006) 308-314
117. Solenkova N.V., Solodushko V., Cohen M.V., and Downey J.M. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am. J. Physiol.: Heart Circ. Physiol. 290 (2006) H441-H449
118. 2b receptors begun after myocardial infarction prevents cardiac remodeling in rats. Circulation (2006) [Epub ahead of print]
119. 2b receptors in cardiac fibroblasts. Am. J. Physiol.: Heart Circ. Physiol. 287 (2004) H2478-H2486
120. 2B adenosine receptor protects against inflammation and excessive vascular adhesion. J. Clin. Invest. 116 (2006) 1913-1923
121. 3 adenosine receptor. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 7432-7436
122. 3 adenosine receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10365-10369
123. 3 adenosine receptors in smooth, cardiac, and skeletal muscle is lethal to embryos. Microvasc. Res. 63 (2002) 61-69
124. 3 adenosine receptor. Circ. Res. 91 (2002) 165-172
125. 3 adenosine receptors. Cardiovasc. Res. 62 (2004) 500-508
126. 3 adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am. J. Physiol.: Heart Circ. Physiol. 283 (2002) H1562-H1568
127. 3 adenosine receptor-mediated protection of the ischemic heart. Vasc. Pharmacol. 42 (2005) 271-279
128. 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275 (2000) 4429-4434
129. 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275 (2000) 4429-4434
130. 3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. Biochim. Biophys. Acta 1500 (2000) 280-290
131. 3 receptors augments adenosine-induced coronary flow in isolated mouse heart. Am. J. Physiol.: Heart Circ. Physiol. 282 (2002) H2183-H2189
132. 3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J. Mol. Cell. Cardiol. 33 (2001) 825-830
133. 3 adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart. Cardiovasc. Res. 53 (2002) 147-155
134. 3 receptors: novel ligands and paradoxical effects. Trends Pharmacol. Sci. 19 (1998) 184-191
135. Burne M.J., Haq M., Matsuse H., Mohapatra S., and Rabb H. Genetic susceptibility to renal ischemia reperfusion injury revealed in a murine model. Transplantation 69 (2000) 1023-1025
136. Majid A., He Y.Y., Gidday J.M., Kaplan S.S., Gonzales E.R., Park T.S., et al. Differences in vulnerability to permanent focal cerebral ischemia among 3 common mouse strains. Stroke 31 (2000) 2707-2714
137. Gorog D.A., Tanno M., Kabir A.M., Kanaganayagam G.S., Bassi R., Fisher S.G., et al. Varying susceptibility to myocardial infarction among C57BL/6 mice of different genetic background. J. Mol. Cell. Cardiol. 35 (2003) 705-708
138. Baker J.E., Konorev E.A., Gross G.J., Chilian W.M., and Jacob H.J. Resistance to myocardial ischemia in five rat strains: is there a genetic component of cardioprotection?. Am. J. Physiol.: Heart Circ. Physiol. 278 (2000) H1395-H1400
139. 3 adenosine receptor. J. Pharmacol. Exp. Ther. (2006 (Sep 19)) [Epub ahead of print]
140. Zavialov A.V., and Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem. J. 391 (2005) 51-57
141. Blackburn M.R., Wakamiya M., Caskey C.T., and Kellems R.E. Tissue-specific rescue suggests that placental adenosine deaminase is important for fetal development in mice. J. Biol. Chem. 270 (1995) 23891-23894
142. Blackburn M.R., Datta S.K., Wakamiya M., Vartabedian B.S., and Kellems R.E. Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. J. Biol. Chem. 271 (1996) 15203-15210
143. Wakamiya M., Blackburn M.R., Jurecic R., McArthur M.J., Geske R.S., Cartwright Jr. J., et al. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 3673-3677
144. Blackburn M.R., Datta S.K., Wakamiya M., Vartabedian B.S., and Kellems R.E. Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. J. Biol. Chem. 271 (1996) 15203-15210
145. Blackburn M.R., Volmer J.B., Thrasher J.L., Zhong H., Crosby J.R., Lee J.J., et al. Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J. Exp. Med. 192 (2000) 159-170
146. Hong H., Chunn J.L., Volmer J.B., Fozard J.R., and Blackburn M.R. Adenosine-mediated mast cell degranulation in adenosine deaminase-deficient mice. J. Pharmacol. Exp. Ther. 298 (2001) 433-440
147. Chunn J.L., Molina J.G., Mi T., Xia Y., Kellems R.E., and Blackburn M.R. Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J. Immunol. 175 (2005) 1937-1946
148. 1 receptor deficiency in normoxic and ischaemic mouse hearts. Cardiovasc. Res. 71 (2006) 79-87
149. Zatta A.J., and Headrick J.P. Mediators of coronary reactive hyperaemia in isolated mouse heart. Br. J. Pharmacol. 144 (2005) 576-587
150. Franco R., Casado V., Ciruela F., Saura C., Mallol J., Canela E.I., et al. Cell surface adenosine deaminase: much more than an ectoenzyme. Prog. Neurosci. 52 (1997) 283-294
151. Hashikawa T., Hooker S.W., Maj J.G., Knott-Craig C.J., Takedachi M., Murakami S., et al. Regulation of adenosine receptor engagement by ecto-adenosine deaminase. FASEB J. 18 (2004) 131-133
152. Ciruela F., Saura C., Canela E.I., Mallol J., Lluis C., and Franco R. Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett. 380 (1996) 219-223
153. 1 adenosine receptors internalize together following agonist-induced receptor desensitization. J. Biol. Chem. 273 (1998) 17610-17617
154. Kitakaze M., Node K., Minamino T., Komamura K., Funaya H., Shinozaki Y., et al. Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5′-nucleotidase. Circulation 93 (1996) 781-791
155. Tsukamoto O., Asanuma H., Kim J., Minamino T., Takashima S., Ogai A., et al. A role of opening of mitochondrial ATP-sensitive potassium channels in the infarct size-limiting effect of ischemic preconditioning via activation of protein kinase C in the canine heart. Biochem. Biophys. Res. Commun. 338 (2005) 1460-1466
156. 2B receptors. J. Exp. Med. 198 (2003) 783-796
157. Koszalka P., Ozuyaman B., Huo Y., Zernecke A., Flogel U., Braun N., et al. Targeted disruption of cd73/ecto-5′-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ. Res. 95 (2004) 814-821
158. Zernecke A., Bidzhekov K., Ozuyaman B., Fraemohs L., Liehn E.A., Luscher-Firzlaff J.M., et al. CD73/ecto-5′-nucleotidase protects against vascular inflammation and neointima formation. Circulation 113 (2006) 2120-2127
159. Eckle T., Grenz A., Faigle M., Weissmuller T., Thompson L., Colgan S.P., et al. Critical role of 5′-ectonucleotidase (CD73) in cardiac ischemic preconditioning. Purinergic Signal. 2 2 (2006) 164 (Abstract)